Latest Allarity Therapeutics News & Updates

See the latest news and media coverage for Allarity. We track all announcements, press releases, and industry mentions in real time, all in one place.

Allarity Therapeutics (Allarity)

Clinical-stage precision medicine company for oncology

allarity.com

Headquarters: Tarpon Springs, United States
Founded year: 2012
Company type: Public company
Number of employees: 10–50

Last updated Today

Latest news about Allarity Therapeutics (Allarity)

In short: Allarity Therapeutics advanced its lead candidate stenoparib into Phase 2 and 3 stages, secured $20 million in funding, and received FDA Fast Track.

Company announcements

May 15 Allarity

Allarity Therapeutics reports Q1 2026 results and clinical progress

Stenoparib development continues in small cell lung and ovarian cancers, with FDA Fast Track designation and new IP allowance.

May 5 Allarity

Allarity Therapeutics advances stenoparib manufacturing for Phase 3

The campaign is on track for Q3 2026 completion, supporting pivotal ovarian cancer trials and FDA approval. All payments are completed with no further cash needed.

April 27 Allarity

Allarity Therapeutics secures US notice of patent allowance

The USPTO issued a Notice of Allowance for the stenoparib DRP® test; patent is expected to grant within three months, potentially providing exclusivity into at least 2039.

April 21 Allarity

Allarity Therapeutics presents two AACR 2026 posters on stenoparib

Posters highlight stenoparib's potential in colorectal cancer via WNT modulation and DRP® linking to improved ovarian cancer survival. Posters available on website.

Media coverage

June 13 The Globe and Mail

Allarity Highlights Stenoparib Progress in New Investor Presentation

Detailed price information for Allarity Therapeutics Inc (ALLR-Q) from The Globe and Mail including charting and trades.

May 18 RTTNews

Allarity Records $2 Mln Net Loss In Q1; Initiates Phase 2 Dosing Of Stenoparib In Lung Cancer

Allarity Therapeutics Inc. (ALLR), a clinical-stage pharmaceutical company, on Friday announced its first quarter financial results, and provided updates on clinical trials for stenoparib in...

May 15 Markets Insider

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer...

May 5 Markets Insider

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced...

Never miss news about Allarity

Track Allarity and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Allarity competitors & trending companies

Browse news for competitors to Allarity and other trending companies.